Investigating how a specific RNA modification affects drug resistance in leukemia stem cells
Role of an Aberrant N6-Methyladenosine-LncRNA Axis in the Development and Maintenance of Drug Resistance through Regulating the Leukemia Stem Cell
This study is looking at how a special change in RNA affects leukemia stem cells that make it hard for treatments to work, with the goal of finding better ways to help patients overcome drug resistance and improve their treatment results.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10917097 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a specific RNA modification, known as N6-methyladenosine (m6A), in the behavior of leukemia stem cells (LSCs) that contribute to drug resistance. The researchers aim to explore how this m6A modification influences the persistence of LSCs during treatment with tyrosine kinase inhibitors (TKIs), which are commonly used in leukemia therapy. By identifying the molecular mechanisms involved, the study seeks to develop new strategies to eliminate these resistant cells and improve treatment outcomes for patients. This could involve targeting the m6A modification to enhance the effectiveness of existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with leukemia who are experiencing drug resistance to current therapies.
Not a fit: Patients with leukemia who are not experiencing drug resistance or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that effectively eliminate drug-resistant leukemia stem cells, improving cure rates and survival for patients with leukemia.
How similar studies have performed: Other research has shown promising results in targeting RNA modifications to overcome drug resistance in cancer, suggesting that this approach may be effective.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Liu, Shujun — Case Western Reserve University
- Study coordinator: Liu, Shujun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.